Cargando…

Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience

Well-differentiated thyroid carcinoma is predominantly a slow-growing malignancy, amendable to treatment, and has an excellent prognosis following thyroidectomy and radioiodine (RAI) therapy. However, patients who fail the initial RAI treatment attempt may require repeated RAI or other treatments an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lubin, David J., Tsetse, Caleb, Khorasani, Mohammad S., Allahyari, Massoud, McGrath, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488882/ https://www.ncbi.nlm.nih.gov/pubmed/34703393 http://dx.doi.org/10.4103/wjnm.WJNM_104_20

Ejemplares similares

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Oral, Aylin, et al.
Publicado: (2018)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Unusual Sites of Metastatic and Benign I 131 Uptake in Patients with Differentiated Thyroid Carcinoma
por: Palaniswamy, Shanmuga S., et al.
Publicado: (2018)

MON-559 Inappropriate Dosing of I-131 in Non-Metastatic Differentiated Thyroid Cancer
por: Alzenaidi, Ahlam, et al.
Publicado: (2019)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for (131)I Administration
por: Gomes-Lima, Cristiane J, et al.
Publicado: (2022)

I-131 Avid Tumor Thrombus in a Case of Poorly Differentiated Thyroid Cancer
por: Gill, Sana Munir, et al.
Publicado: (2023)

Usefulness of second (131)I treatment in biochemical persistent differentiated thyroid cancer patients
por: Gambale, Carla, et al.
Publicado: (2023)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident
por: Brenner, Alina V., et al.
Publicado: (2011)

Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on (131)I-SPECT/CT
por: Wang, Feng, et al.
Publicado: (2021)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
por: Shinto, Ajit S., et al.
Publicado: (2013)

Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment
por: Hussein, Osama, et al.
Publicado: (2013)

Efficacy of Dosimetric Versus Empiric Prescribed Activity of (131)I for Therapy of Differentiated Thyroid Cancer
por: Klubo-Gwiezdzinska, Joanna, et al.
Publicado: (2011)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
por: van der Boom, Trynke, et al.
Publicado: (2021)

Dosimetry during adjuvant (131)I therapy in patients with differentiated thyroid cancer-clinical implications
por: Szumowski, Piotr, et al.
Publicado: (2021)

Analysis of the incidence and influencing factors of hyponatremia before (131)I treatment of differentiated thyroid carcinoma
por: Cao, Jing-Jia, et al.
Publicado: (2021)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

MON-LB83 The Initial Dose of (131)I as a Potential Independent Predictor for Residual/Relapsed Disease in Pediatric Differentiated Thyroid Cancer
por: Bustamante Escobar, Carmen L, et al.
Publicado: (2020)

Transcriptional response to (131)I exposure of rat thyroid gland
por: Rudqvist, Nils, et al.
Publicado: (2017)

Effect of (131)I ‘clear residual thyroid tissue’ after surgery on the function of parathyroid gland in differentiated thyroid cancer
por: ZHAO, ZHI-HUA, et al.
Publicado: (2015)

Dosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models
por: Josefsson, Anders, et al.
Publicado: (2014)

Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy
por: Zubair Hussain, Syed, et al.
Publicado: (2014)

Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131
por: PICIU, DOINA, et al.
Publicado: (2016)

DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131)
por: Prpić, Marin, et al.
Publicado: (2019)

Iodine-131 and Thyroid Function
por: Sun, Wenjie
Publicado: (2014)

Psychological impact of (131)I radioprotection measures on thyroid cancer patients
por: BARBUS, ELENA, et al.
Publicado: (2018)

I(131) Accumulation in Hydrocele in the Setting of Metastatic Papillary Carcinoma Thyroid
por: Seetharam, SJ, et al.
Publicado: (2022)

SUN-478 Poorly Differentiated Thyroid Cancer Arising from a Hyperfunctioning Nodule Treated with I-131
por: Miller, Eli, et al.
Publicado: (2020)

FDG PET Predicts the Effects of (131)I and Prognosis for Patients with Bone Metastases from Differentiated Thyroid Carcinoma
por: Wang, Danyang, et al.
Publicado: (2020)

Low-Iodine Diet of 4 Days Is Sufficient Preparation for (131)I Therapy in Differentiated Thyroid Cancer Patients
por: Dekker, Bernadette L, et al.
Publicado: (2021)

Prediction of thyroidal (131)I effective half-life in patients with Graves' disease
por: Zhang, Ruiguo, et al.
Publicado: (2017)

Thyroid dose assessments due to inhalation of (131)I for nuclear medicine workers
por: Liu, Gang, et al.
Publicado: (2022)

Radioactive Body Burden Measurements in (131)Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body (131)Iodine Clearance
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3otq6gf9cgma5gj83trcg5h8kq